Recently, several groups have reported that transgenic expression of IL-7, either alone or with co-expression of CCL19, in CAR-T cells has resulted both in enhanced CAR-T cell persistence and in improved anti-tumor response (44–49). Here, IL7 is linked to neoplasm.